“…For HBV-HCC patients, several miRNAs from HCC tissues or blood are found to be significantly correlated with overall survival, diseases-free survival (DFS) and progression-free survival (Table 6 ). For tissue miRNAs, higher expression of miR-122[ 54 , 55 ], miR-143[ 55 ], miR-145[ 56 ], miR-193b[ 57 ], miR-203a[ 58 ], miR-216b[ 59 ], miR-375[ 55 , 60 ], and miR-384[ 61 ] is associated with a better prognosis, and higher expression of miR-9-3[ 62 ], miR-10b[ 62 ], miR-21[ 56 ], miR-29a-5p[ 63 ], miR-31[ 62 ], miR-106b[ 64 ], miR-224[ 55 ], miR-371a-5p[ 27 ], miR-519c[ 62 ], miR-522[ 62 , 65 ], miR-523[ 65 ], miR-3188[ 28 ], miR-3682-3p[ 66 ], miR-3660[ 62 ], miR-4784[ 62 ], miR-5188[ 67 ], and miR-6883[ 62 ] is associated with a significantly poorer long-term prognosis. For circulating miRNAs, higher expression of miR-150[ 13 ], miR-223-3p[ 68 ], and miR-768-3p[ 20 ] is associated with a better prognosis, higher expression of miR-24-3p[ 33 ], miR-29a-3p[ 69 ], miR-96[ 34 ], miR-155[ 70 ], miR-192-5p[ 69 ], and miR-487b[ 18 , 19 ] is associated with a significantly poorer long-term prognosis.…”